Published in Hum Vaccin Immunother on March 30, 2016
Factors related to non-compliance to HPV vaccination in Roraima-Brazil: a region with a high incidence of cervical cancer. BMC Health Serv Res (2016) 0.75
Human papillomavirus vaccination: the population impact. F1000Res (2017) 0.75
Incidence of early loss of pregnancy. N Engl J Med (1988) 9.21
Deaths: preliminary data for 2011. Natl Vital Stat Rep (2012) 5.62
Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA (2009) 5.58
Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2014) 4.50
Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res (2011) 3.88
Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med (2011) 3.63
National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years--United States, 2014. MMWR Morb Mortal Wkly Rep (2015) 3.48
Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014--United States. MMWR Morb Mortal Wkly Rep (2014) 3.41
Increasing fear of adverse effects drops intention to vaccinate after the introduction of prophylactic HPV vaccine. Arch Gynecol Obstet (2012) 2.83
Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep (2015) 2.73
Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013 - United States. MMWR Morb Mortal Wkly Rep (2013) 2.59
Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. JAMA (2015) 2.22
Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol (2009) 2.13
Reasons for not vaccinating adolescents: National Immunization Survey of Teens, 2008-2010. Pediatrics (2013) 2.01
Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J (2004) 1.76
Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine (2011) 1.70
Real-time vaccine safety surveillance for the early detection of adverse events. Med Care (2007) 1.66
A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD. Vaccine (2010) 1.65
Acute disseminated encephalomyelitis following vaccination against human papilloma virus. Neurology (2009) 1.61
The Vaccine Safety Datalink: a model for monitoring immunization safety. Pediatrics (2011) 1.60
HPV vaccination crisis in Japan. Lancet (2015) 1.55
Postural tachycardia syndrome. Circulation (2008) 1.54
The Vaccine Safety Datalink project. Pharmacoepidemiol Drug Saf (2002) 1.39
Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis (2010) 1.37
Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. J Intern Med (2013) 1.37
Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr (2010) 1.35
Safety of human papillomavirus vaccines: a review. Drug Saf (2013) 1.25
Post-licensure monitoring of HPV vaccine in the United States. Vaccine (2010) 1.24
Safety of quadrivalent human papillomavirus vaccine administered routinely to females. Arch Pediatr Adolesc Med (2012) 1.23
Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions. Pediatr Infect Dis J (2007) 1.23
Mechanisms of premature ovarian failure. Ann Endocrinol (Paris) (2003) 1.20
Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women. Clin Infect Dis (2014) 1.06
Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women. Clin Infect Dis (2013) 1.05
An unmasking phenomenon in an observational post-licensure safety study of adolescent girls and young women. Vaccine (2012) 1.01
The role of the Vaccine Adverse Event Reporting system (VAERS) in monitoring vaccine safety. Pediatr Ann (2004) 1.00
Complex regional pain syndrome following immunisation. Arch Dis Child (2012) 0.98
Safety of human papillomavirus (HPV) vaccines: a review of the international experience so far. Vaccine (2009) 0.93
An immunological insight into premature ovarian failure (POF). Autoimmun Rev (2010) 0.92
Orthostatic intolerance and postural tachycardia syndrome as suspected adverse effects of vaccination against human papilloma virus. Vaccine (2015) 0.91
An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015. Pediatr Infect Dis J (2015) 0.91
Quadrivalent human papillomavirus vaccine and the risk of venous thromboembolism. JAMA (2014) 0.90
Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial. J Infect Dis (2013) 0.85
Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink, 2008-2011. Vaccine (2015) 0.85
Autoimmune diseases after adolescent or adult immunization: what should we expect? CMAJ (2007) 0.85
Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescents and young adults. Vaccine (2014) 0.84
Premature ovarian failure 3 years after menarche in a 16-year-old girl following human papillomavirus vaccination. BMJ Case Rep (2012) 0.83
Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol (2015) 0.83
Identification of premature ovarian failure patients with underlying autoimmunity. J Womens Health Gend Based Med (2000) 0.82
Autoimmune hepatitis type 2 following anti-papillomavirus vaccination in a 11-year-old girl. Vaccine (2011) 0.81
Can HPV immunisation cause ADEM? Two case reports and literature review. Mult Scler (2013) 0.80
Political and news media factors shaping public awareness of the HPV vaccine. Womens Health Issues (2013) 0.79
Safety of quadrivalent human papillomavirus vaccine (Gardasil) in pregnancy: adverse events among non-manufacturer reports in the Vaccine Adverse Event Reporting System, 2006-2013. Vaccine (2014) 0.79
Adolescent Premature Ovarian Insufficiency Following Human Papillomavirus Vaccination: A Case Series Seen in General Practice. J Investig Med High Impact Case Rep (2014) 0.78
Final report on exposure during pregnancy from a pregnancy registry for quadrivalent human papillomavirus vaccine. Vaccine (2015) 0.77
HPV Vaccination and Complex Regional Pain Syndrome: Lack of Evidence. EBioMedicine (2015) 0.76
Vaccination and 30-Day Mortality Risk in Children, Adolescents, and Young Adults. Pediatrics (2016) 0.76
Postural Orthostatic Tachycardia With Chronic Fatigue After HPV Vaccination as Part of the "Autoimmune/Auto-inflammatory Syndrome Induced by Adjuvants": Case Report and Literature Review. J Investig Med High Impact Case Rep (2014) 0.76
Evaluation of the risk of venous thromboembolism after quadrivalent human papillomavirus vaccination among US females. Vaccine (2015) 0.76
Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. Neurology (2005) 0.76